This study sought to assess the incidence, predictors, and outcome of drug-eluting stent (DES) thrombosis in real-world clinical practice.
Background
The DES thromboses in randomized trials could not be comparable to those observed in clinical practice, frequently including off-label indications.
Methods
We designed a large-scale, nonindustry-linked multicentered registry, with 20 centers in Spain. The participant centers provided follow-up data for their patients treated with DES, reporting a detailed standardized form in the event of any angiography-documented DES-associated thrombosis occurring.
Results
Of 23,500 patients treated with DES, definite stent thrombosis (ST) developed in 301: 24 acute, 125 subacute, and 152 late. Of the late, 62 occurred Ͼ1 year (very late ST). The cumulative incidence was 2% at 3 years. Antiplatelet treatment had been discontinued in 95 cases (31.6%). No differences in incidences were found among stent types. Independent predictors for subacute ST analyzed in a subgroup of 14,120 cases were diabetes, renal failure, acute coronary syndrome, ST-segment elevation myocardial infarction, stent length, and left anterior descending artery stenting, and for late ST were ST-segment elevation myocardial infarction, stenting in left anterior descending artery, and stent length. Mortality at 1-year follow-up was 16% and ST recurrence 4.6%. Older age, left ventricular ejection fraction Ͻ45%, nonrestoration of Thrombolysis In Myocardial Infarction flow grade 3, and additional stenting were independent predictors for mortality.
Conclusions
The cumulative incidence of ST after DES implantation was 2% at 3 years. No differences were found among stent types. Patient profiles differed between early and late ST. Short-term prognosis is poor, especially when restoration of Mortality rates, myocardial infarction, and stent thrombosis (ST) with drug-eluting stents (DES) in the combined analyses of multiple randomized trials are comparable to those observed with bare-metal stents (BMS), although patients included in these trials had a low risk profile (1, 2) .
Initial clinical practice registries provided data on thrombosis rates, frequently including off-label indications for DES. In these studies the incidence of stent thrombosis was around 1.3%, with a late thrombosis rate of 0.35% to 0.8% depending on the definitions applied, and different predictors for thrombosis were identi-fied (3-6). Nevertheless, there is a paucity of data on the magnitude of DES-associated thrombosis in standard cardiology practice, its incidence years after implantation, and the predisposing factors, specifically for late ST.
The current study was designed as a multicenter industryindependent registry with the aim of resolving these areas of doubt regarding DES thrombosis in real-world cardiology practice.
Methods
This is an industry-independent prospective registry. All coordination between the 20 participating centers across Spain, the adjudication process, and analyses were performed centrally at the Hospital Universitario Marques de Valdecilla in Santander. Patient selection. Since the introduction of DES in Spain in June 2002, its penetration has increased from 5% in 2002 to 59% in 2006 and has varied widely in different centers (7) . All of the participating centers were required to fill in a detailed standardized form in the event of any angiographically-documented DES-associated thrombosis occurring since the introduction of DES. Patients gave informed consent for the inclusion of their data in the registry, and anonymity was guaranteed. 
Figure 1 Cumulative Incidence of ST
A Kaplan-Meier curve shows the survival free of definite stent thrombosis (ST) for the overall cohort and the subsequent cumulative incidence of ST. This incidence was 1.2%, 1.6%, and 2% at 1, 2, and 3 years, respectively. ST ‫؍‬ stent thrombosis STEMI ‫؍‬ ST-segment elevation myocardial infarction using those variables with p Ͻ 0.25 in the univariate analysis, but variable of antiplatelet therapy discontinuation was not included because the data were not available for all cases without ST. A stepwise Cox proportional hazards model was used to identify independent predictors of mortality and recurrent thrombosis after the ST event. Kaplan-Meier survival curves analyses were used to show the cumulative incidence of ST and in comparing mortality and recurrent thrombosis of late versus early events. All probability values were 2-sided, and values of p Ͻ 0.05 were considered statistically significant. The statistical package SPSS 11.0 (SPSS Inc., Chicago, Illinois) was used throughout.
Results
Between June 2002 and January 2007, a total of 23,500 patients were treated with 34,075 DES: 37% with sirolimus-eluting stents (SES) and 63% with paclitaxeleluting stents (PES) in 20 centers. With a median follow-up of 22 months (11 to 32, 25th percentile and 75th percentile, respectively), 301 patients (1.28%) had documented ST: 24 (8%) were acute (Ͻ24 h), 125 (41.5%) were subacute (24 h to 30 days), 90 (30%) were late (1 month to 12 months), and 62 (20.6%) were very late (Ͼ1 year). Figure 1 shows the cumulative survival free of ST. Cumulative incidence at 3 years was 2% without differences between stent types (1.97% for PES and 2.03% for SES; p ϭ 0.8). The clinical characteristics of the groups with and without thrombosis are described in Table 1 . The clinical and procedural characterization of the ST types are summarized in Table 2 . Compared with the acute/subacute ST, the cases with late ST were younger men, with a lower incidence of diabetes, with larger vessels and less frequent suboptimal angiographic outcomes. Antiplatelet treatment at the time of the event is presented in Table 3 . At discharge from hospital, the duration of combined antiplatelet therapy was 8 Ϯ 3 months. Overall, 95 patients (31.6%) were not taking the prescribed antiplatelet therapy. The reason for treatment cessation was bleeding in 12 patients, surgical intervention in 11, allergic reaction to antiplatelet drugs in 6, and noncompliance in 66 patients. Among those with late ST, 70 patients had ST after properly completing the dual antiplatelet treatment period, a median time of 6.3 months (3 to 15.8 months) after discontinuation of clopidogrel, and only 5 (7.1%) within the first month.
Multivariate analysis was performed in a subgroup of 14,120 patients (Table 4) . This subgroup was comparable in all analyzed characteristics to the overall cohort. The independent predictors for acute/subacute thrombosis were acute coronary syndrome, ST-segment elevation myocardial infarction (STEMI), renal failure, stent in left anterior descending artery (LAD), stent length, and diabetes and for late thrombosis were STEMI, stent in LAD, and stent length. Values are presented as mean Ϯ standard deviation, n (%), or median (interquartile range). *Any of the following: stent underexpansion noted by angiography defined as in-stent residual stenosis Ͼ10%; final Thrombolysis In Myocardial Infarction flow grade Ͻ3; noncovered dissection at stent margins; significant disease in the adjacent reference segments defined as a stenosis Ͼ25%. EF ϭ ejection fraction; other abbreviations as in Table 1 .
Antiplatelet Treatment at the Time of ST Table 5 summarizes the treatment and outcomes comparing the groups with acute/subacute and late ST. The Kaplan survival analysis for the combined end point of death and recurrent thrombosis did not show significant differences between the groups (hazard ratio 1.2, 95% confidence interval 0.74 to 2.05, p ϭ 0.4). The independent predictors for mortality and thrombosis recurrence after the ST event are shown in Table 6 .
Discussion
The use of DES in cardiology practice has been extended and frequently includes off-label indications. Hence, the incidence of ST in real-world practice is not the same as that observed in the trials. Iakovou et al. (3) found a 1.3% rate in 2,229 patients. The group from Rotterdam reported 1% and 0.35% rates for angiographic subacute and late ST, respectively (4,5). The group from the Washington Hospital Center observed a rate of 1.27% in 2,794 patients with renal failure, bifurcation, in-stent restenosis, and clopidogrel discontinuation as independent predictors (6) . Finally, the Bern-Rotterdam registry yielded a cumulative incidence of 2.9% at 3 years in 8,146 patients (8) . Diabetes and acute coronary syndrome were identified as independent predictors. Predictors for late ST. Similar to our results, the registries cited above noted that early discontinuation of antiplatelet therapy was a relatively common finding in patients with late ST (3-6,8) . The association of STEMI with late ST has been noted in other clinical registries. The Rotterdam group reported a 2-year incidence of 3.2% for angiographic thrombosis in 812 STEMI patients treated with DES (9). Conversely, the recently published randomized trials showed no differences in thrombosis at 1 year between BMS and DES (10, 11) .
The LAD stent location had been observed, well over a decade ago, as a predictor for ST (12) Abbreviations as in Table 1 .
Clinical Presentation, Treatment, and Outcome Values are mean Ϯ standard deviation or n (%). PCI ϭ percutaneous coronary intervention; TIMI ϭ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1 . Table 5 .
Independent Predictors for Mortality and Recurrent Thrombosis
989 JACC Vol. 51, No. 10, 2008 de la Torre-Herná ndez et al. March 11, 2008:986-90 Nationwide Study on DES Thrombosis published case reports of late stent thrombosis shows that 74% of them had had DES implanted in the LAD artery (13) . The LAD location in our study was frequently associated with a recent history of infarction in this territory. DES versus BMS thrombosis. Our registry uses angiographic documentation of ST and certainly underestimates the real incidence of ST. The overall incidence of DESassociated documented thrombosis results are slightly higher than reported previously with BMS (14, 15) . A rate of 0.6% to 0.8% for late-onset thrombosis with BMS has been reported (16); however, these events occurred very exceptionally Ͼ12 months post-procedure in the absence of prior brachytherapy. Treatment and clinical outcome. The implantation of an additional stent was associated with an adverse outcome, whereas the infusion of abciximab reduced the recurrence of ST episodes. The use of new stents should be restricted to those with significant residual stenosis after balloon dilatation or with stent-edge dissections. The use of intravascular ultrasound could identify predisposing mechanical factors and could help guide interventions. In fact, detailed intravascular ultrasound studies of 12 of these patients with confirmed DES thrombosis have been previously reported (17) . Study limitations. This is the largest registry available to date addressing DES thrombosis; however, several limitations should be noted. The study is observational in nature and has inherent disadvantages. This is a registry of angiographically documented (definite) thrombosis, and as such, the rates of DES are underestimated. The ST incidence would have been closer to reality if we had included probable and possible ST cases (18) . However, we felt that clear, clinical, angiographic and procedural characteristics of ST patients were appropriate in defining the profile and variables associated. The multivariate analysis was conducted in a subgroup of patients within the overall cohort; nevertheless, this was a clearly representative group, being the largest multivariate analysis available to date in the literature. Finally, as in other registries (8), it was not possible to ascertain retrospectively the compliance with antiplatelet treatment in patients without ST.
Conclusions
In this multicenter registry of DES, the cumulative incidence of angiographically documented stent thrombosis was 2% at 3 years. No differences were found between paclitaxeleluting and sirolimus-eluting stents. The profiles of patients with early and late thrombosis were different. The shortterm prognosis is poor, especially when the restoration of normal flow has failed. 
